Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.00 -0.92% 1,402.00 1,404.00 1,407.00 1,426.00 1,387.00 1,406.00 208,325 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 260.0 8.4 6.0 233.7 3,179

Abcam Share Discussion Threads

Showing 1001 to 1014 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
06/2/2020
15:39
Is a testing kit something Abcam could be working on ?
cokehookerscars
05/2/2020
17:05
Fair point.
bulltradept
05/2/2020
16:22
Yes but China growth could take a hit from it, plus zero hedge are running a story about the figures being significantly higher, leaked official data. Check it out today.
bulltradept
05/2/2020
16:12
https://otp.investis.com/clients/uk/abcamplc/rns/regulatory-story.aspx?cid=128&newsid=1358008 Catalogue revenue, representing approximately 95% of the total, grew by 11.6% in the first half on a reported basis and 9.1% on a constant currency basis, with all regions and product categories growing faster than estimated underlying market growth rates. Revenue in China grew faster than market at 17.4% in the year on a constant currency basis, representing over 17% of total company sales.
bulltradept
05/2/2020
16:09
None known China? Don't they produce over there, or markets etc?
bulltradept
05/2/2020
13:54
Use the ignore button, a lot have.
bulltradept
11/1/2020
08:50
Can't you post a summary too? Stop doing silly things!
bathcoup
10/1/2020
08:19
I have to be careful about confirmation bias as I have sold a lot of ABC. Revenue "11.6% in the first half on a reported basis and 9.1% on a constant currency basis," Removing China (growth of 17.4%) I calculate ROW growth of 9.4% This would be 7.4% on a constant currency basis. Gross margin constant - 'adjusted operating profit margin' lower end of 25% - 28%. Doesn't say what the adjustment is and doesn't consider the continuing capital expenditure or comment on profit. Two acquisitions are expected to contribute approximately £4m of incremental revenue in the current fiscal year (FY2020) and be neutral to adjusted earnings. ""We have recently set out ambitious plans to double the scale of our business and we are making good progress in investing in, and scaling up, the company." So, big ambitions and ex growth but spending money like water and not saying anything about profit. apad
apad
10/1/2020
08:03
Watch this bomb today!
lenzcrafter
18/12/2019
16:11
Should have had a nibble this morning! Doh
lenzcrafter
18/12/2019
08:24
announcement - but I cant find it
slogsweep
18/12/2019
08:14
Why the huge drop??
lenzcrafter
16/12/2019
11:01
Following on from my previous Open Orphans (ORPH) post, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform. At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020
sunningdale1
15/11/2019
21:21
A beautiful day, nice and blue.
lenzcrafter
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
LSE
ABC
Abcam
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 05:18:43